ARTICLE | Emerging Company Profile
Going SPLUNCing
Spyryx is using peptides against ENaC to treat CF regardless of CFTR mutation
August 3, 2015 7:00 AM UTC
Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than therapies targeting CFTR.
CF is caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) channel that result in depletion of airway surface liquid and abnormally adherent mucus. Spyryx's peptides target the epithelial sodium channel (ENaC), which conducts sodium and water away from the airway surface, and becomes hyperactive when CFTR is defective...